177-lutetium-PSMA and 225-actinium-PSMA or Peptide Receptor Treatments
177-lutetium-PSMA and 225-actinium-PSMA in the treatment of metastatic prostate cancer
In January 2017, we were the first health care provider in Finland to use 177-lutetium-PSMA* drug therapy in the treatment of advanced prostate cancer, which enables destroying metastases outside the bones efficiently without any severe adverse effects. 225-actinium-PSMA drug was used in 2021 for the first time.
Before the treatment, we carry out a diagnostic PET scan using F-PSMA tracers to ensure that 177-lutetium-PSMA or 225-actinium-PSMA uptake occurs in the metastases.
177-lutetium-PSMA and 225-actinium-PSMA therapies are administered intravenously, and its their most common side effect is a dry mouth. Depending on the individual, the treatment is typically performed 2–6 times approximately every 4–6 weeks (177-lutetium-PSMA) or approximately every 8 week (225-actinium-PSMA).
The multidisciplinary team in charge of peptide-receptor therapies at Docrates Cancer Center is led by Chief Physician in Nuclear Medicine Jukka Kemppainen.
*177-lutetium-PSMA och 225-actinium-PSMA are still experimental treatments, and have a special permission for compassionate use by the Finnish Medicines Agency (Fimea). The international randomised controlled trials are also in their third phase, after which official and more detailed Current Care Guidelines can probably be issued for the cancer cases selected for treatment. However, some results were already presented in October’s ESMO2018 conference, according to which the dose escalation study had shown that even a dose three times larger than that proved effective at Docrates was found safe and well tolerated without the appearance of the toxicity that restricts the dosage.
Cancer and Coronavirus – FAQ
The coronavirus is a concern among cancer patients. We listed the most common concerns and the answers to them.Read more
One type of cancer is distinct from others due to its painfulness—these everyday methods can alleviate the pain, and sauna is not necessarily one of them
As cancer becomes metastasised, it typically causes more pain. Oncologist Olga Maslennikova from Docrates Cancer Center shares the best ways...Read more
Christmas and public holiday opening hours
Docrates is open, and we are here for you even during Christmas time. See our Christmas and public holiday opening...Read more
Confusion and fear of death are present when a cancer diagnosis is made
Looking after the mental well-being of someone who has been diagnosed with cancer is an essential part of recovery from...Read more
Why come to Docrates Cancer Center?
- Top cancer experts and effective treatments without delay even during epidemic.
- Individual care. You have your own care team - your doctor and your nurse.
- Front line cancer treatment. Latest medical technology combined with proven expertise in cancer care.
- Experience in treating international patients from over 60 countries. Multilingual personnel.